Microbix completes $1.3 million private placement

Microbix Biosystems (TSX:MBX) has closed a $1.3 million private placement by issuing 3,714,286 common shares at a price of 35 cents each.  The stock closed at 35 cents last Friday. “We felt it was prudent to strengthen our balance sheet while finalizing our partnering arrangements,” CEO William Gastle said in a statement, adding that proceeds [...]

Microbix cleared to sell Kinlytic

Health Canada has issued a drug identification number for Kinlytic, formerly known as urokinase, allowing Microbix Biosystems (TSX:MBX) to sell its clot-busting therapy in Canada and markets worldwide. In a statement, Toronto-based Microbix said it will now submit an application to Health Canada for approval of its recently acquired urokinase inventory and targets its release [...]

Microbix at “inflection point” bringing pipeline forward

It was a pretty seamless transition for Mark Cochran last year. His latest gig, running a neurosciences institute in West Virginia for the Rockefellers, had come to an end.  He’d been a director of Microbix Biosystems (TSX: MBX) of Toronto since 1990 and a long-time friend of CEO Bill Gastle.  So, when Mr. Gastle asked [...]